ICD-10 Β· E28.2
Polycystic ovary syndrome(PCOS)
PCOS is the most common endocrine disorder in women of reproductive age, affecting roughly 8-13% globally. It is characterized by irregular menstrual cycles, excess androgens, and polycystic ovaries. GLP-1 medications are increasingly used off-label for the obesity and insulin-resistance components of PCOS.
Medically reviewed by Dr. Jane Novak, MD, MPH on June 1, 2026
This is general health information, not medical advice. Talk to a licensed clinician about diagnosis and treatment options.
Overview
Symptoms
- Irregular periods
- Infertility
- Acne and oily skin
- Hirsutism (excess hair growth)
- Weight gain
- Hair thinning
- Insulin resistance
Risk factors
- Family history of PCOS
- Insulin resistance
- Obesity
- Sedentary lifestyle
Treatment options
- Hormonal contraceptives
- Metformin
- Spironolactone (anti-androgen)
- GLP-1 receptor agonists (off-label)
- Letrozole/clomiphene for fertility
- Lifestyle intervention
GLP-1 evidence for polycystic ovary syndrome
Editorial grades summarizing study quality and convergence. How we grade.
| Claim | Grade | Basis |
|---|---|---|
GLP-1 therapy improves insulin sensitivity in PCOS Source: Reproductive Biology & Endocrinology, 2023 Small-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial | BModerate evidence | Small-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial |
GLP-1 weight loss restores ovulatory cycles in some patients Observational + small trial data; ovulation rate ~30-50% higher than controls | BModerate evidence | Observational + small trial data; ovulation rate ~30-50% higher than controls |
GLP-1 directly treats hyperandrogenism (acne, hirsutism) Effect appears secondary to weight loss + insulin improvement, not androgen-specific | CLimited evidence | Effect appears secondary to weight loss + insulin improvement, not androgen-specific |
GLP-1 is FDA-approved for PCOS No FDA-approved indication for PCOS; use is off-label, weight-driven | FNo evidence | No FDA-approved indication for PCOS; use is off-label, weight-driven |
Related GLP-1 medications
Mounjaro
GIP/GLP-1 dual receptor agonist Β· ~$1023.04/mo
View detailsWegovy
GLP-1 receptor agonist Β· ~$1349.02/mo
View detailsOzempic
GLP-1 receptor agonist Β· ~$935.77/mo
View detailsNot sure which medication is right for you? Our quiz matches you with providers based on state, insurance, and budget.
Take the GLP-1 quizCommon questions readers ask
- Do I need to exercise on Wegovy?
- Yes β resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable. Full evidence-graded answer
- How fast do results show on GLP-1?
- Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates. Full evidence-graded answer
- Why am I not losing weight on Wegovy?
- Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose. Full evidence-graded answer
- Can I build muscle on a GLP-1?
- Yes β with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat. Full evidence-graded answer
- Can GLP-1 help with PCOS?
- Yes β primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven. Full evidence-graded answer
- Does GLP-1 work for type 1 diabetes?
- No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring. Full evidence-graded answer
Sources
- International evidence-based guideline for PCOS β Monash University / Endocrine Society
- GLP-1 receptor agonists in PCOS β Reproductive BioMedicine Online
Was this page helpful?